Urine test strip

HealthWell Foundation Launches Fund to Provide Financial Assistance to Individuals Living with IgA Nephropathy

Retrieved on: 
Tuesday, January 17, 2023
Disease, Immunoglobulin A, Blood, Entrepreneurship, Kidney, Kidney disease, Insurance, Urine, Dialysis, Mayo Clinic, Chronic kidney disease, Urine test strip, Immune system, Patient, IgA nephropathy, HIV disease progression rates, Prescription, Inflammation, Health insurance, Pharmaceutical industry

GERMANTOWN, Md., Jan. 17, 2023 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with IgA nephropathy. Through the new fund, HealthWell will provide up to $9,000 in medication copayment or insurance premium assistance to eligible patients with annual household incomes up to 500 percent of the federal poverty level for the management of their disease. The fund will also provide assistance with standard laboratory monitoring including blood tests and urinalysis. 

Key Points: 
  • GERMANTOWN, Md., Jan. 17, 2023 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with IgA nephropathy.
  • The fund will also provide assistance with standard laboratory monitoring including blood tests and urinalysis.
  • "For those living with IgA, disease progression can lead to dialysis or even kidney transplant, in some cases.
  • To determine eligibility, medications and laboratory monitoring covered, and apply for financial assistance, visit HealthWell's IgA Nephropathy Fund page.

Global In-Vitro Diagnostics (IVD) Market Report 2022: Introduction of Disease-Specific Biomarkers and Tests Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Medical Devices, Hospital, Degenerative disease, Immunoassay, Infection, Hemostasis, HIV/AIDS, Clifton Springs Hospital & Clinic, POC, Microbiology, Nephrology, Government, IVD, Coagulation, Cardiology, Urine test strip, Diagnosis, Growth, Diabetes, Region, Prevalence, Patient, Data management, USD, Medical device, Clinical urine tests, Software, Hematology

The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.

Key Points: 
  • The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.
  • On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software.
  • The reagents & kits segment accounted for the largest share of the IVD market in 2021.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.

Urinalysis Market Size, Share & Trends Analysis Report 2022: A $5.4 Billion Market by 2030 - Focused Research on Disease Screening, Pregnancy & Fertility Testing - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Health, Medical Supplies, Medical Devices, Gastrointestinal tract, TM, Bilirubin, Fertility, Indolent T cell lymphoproliferative disorder of the gastrointestinal tract, Urine test strip, Laboratory, USD, Urinary tract infection, Disease, Kidney disease, WHO, Patient, Ketone, World Health Organization, Transplant, Kidney, Conditional sentence, Glucose, Incidence, UTI, Prevalence, Diagnosis, Creatinine, Marketing, Liver disease, Liver, Medical device, Dietary supplement, Health insurance, Dentistry, Overmyer Network

The "Urinalysis Market Size, Share & Trends Analysis Report by Product, by Application (Disease Screening {UTI, Kidney Disease}, Pregnancy & Fertility Testing), by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urinalysis Market Size, Share & Trends Analysis Report by Product, by Application (Disease Screening {UTI, Kidney Disease}, Pregnancy & Fertility Testing), by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global urinalysis market size is expected to reach USD 5.4 billion by 2030.
  • The market is expected to witness a CAGR of 4.6% from 2022 to 2030.
  • Increasing geriatric population and the subsequent increase in age related diseases in developed and developing regions will positively influence urinalysis market growth.

In Vitro Diagnostics Market worth $144.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023
Government, Cancer, Nephrology, POC, HIV/AIDS, Cardiology, Urine test strip, Microbiology, Hemostasis, Growth, Patient, Infection, Degenerative disease, IVD, Physician, Hematology, Data management, Diabetes, Prevalence, Medical device, Healthcare

The high growth in this market is attributed to the technological advancements in diagnostic analyzers.

Key Points: 
  • The high growth in this market is attributed to the technological advancements in diagnostic analyzers.
  • Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics.

In Vitro Diagnostics Market worth $144.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023
Government, Cancer, Nephrology, POC, HIV/AIDS, Cardiology, Urine test strip, Microbiology, Hemostasis, Growth, Patient, Infection, Degenerative disease, IVD, Physician, Hematology, Data management, Diabetes, Prevalence, Medical device, Healthcare

The high growth in this market is attributed to the technological advancements in diagnostic analyzers.

Key Points: 
  • The high growth in this market is attributed to the technological advancements in diagnostic analyzers.
  • Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics.

EQS-News: Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES

Retrieved on: 
Sunday, December 18, 2022
Breast cancer, Coagulation, Cell, Tmax, DNA repair, Melanoma, Neoplasm, Survival rate, Reactive oxygen species, GLP, Mortality, Animal, Laboratory rat, FDA, Catastrophic illness, Safety, DNA, Engineering, Cancer, Hardness, ADC, RATS, Dog, Control, Systemic inflammation, Female, Mouse, Erythema, Urine test strip, Vaccine, News, Urine, CSE, Defense, Disease, Toxicity, USD, Infection, Growth, Plasma, Therapy, Injection, Male, Patient, Security (finance), Pharmaceutical industry

In the past 16 months, Defence engineered a large library of AccumTM variants exhibiting differential effects on both immune and cancer cells.

Key Points: 
  • In the past 16 months, Defence engineered a large library of AccumTM variants exhibiting differential effects on both immune and cancer cells.
  • Interestingly, AccuTOXTM administration synergises with different immune-checkpoints (anti-PD-1, anti-CTLA4 and anti-CD47) making it a highly mouldable molecule adaptable to a myriad of solid cancer indications.
  • GLP studies in rodents revealed no adverse effects for AccuTOXTM.
  • Upon completing the GLP study in rats, Defence followed up with a second set of GLP studies in Beagle dogs.

Clinical Chemistry Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
Thermo Fisher Scientific, CVD, Infection, Randox Laboratories, Cancer, COVID-19, Risk, Serum, Siemens, Conditional sentence, Eastman Kodak Co. v. Image Technical Services, Inc., Research report, Stroke, Death, Growth, Urine test strip, Public health, Prevalence, Liver function tests, Disability, Cardiovascular disease, Diabetes, World Health Organization, Degenerative disease, Urine, USD, Acquisition, Water, Ortho Clinical Diagnostics, Myocardial infarction, Laboratory, Plasma, Chemistry, Chronic condition, Patient, Hospital, Abbott Laboratories, Clinical chemistry, WHO, Acute kidney injury, Organization, Fine chemical, Pharmaceutical industry

The global clinical chemistry market is expected to grow from $ 11.93 billion in 2021 to $ 12.76 billion in 2022 at a compound annual growth rate (CAGR) of 7%.

Key Points: 
  • The global clinical chemistry market is expected to grow from $ 11.93 billion in 2021 to $ 12.76 billion in 2022 at a compound annual growth rate (CAGR) of 7%.
  • The clinical chemistry market is expected to grow to $ 15.69 billion in 2026 at a CAGR of 5.3%.
  • The regions covered in the clinical chemistry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The clinical chemistry market research report is one of a series of new reports that provides clinical chemistry market statistics, including clinical chemistry industry global market size, regional shares, competitors with clinical chemistry market share, detailed clinical chemistry market segments, market trends and opportunities, and any further data you may need to thrive in the clinical chemistry industry.

Saint Francis Health System Partners with DispatchHealth to Bring New In-Home Medical Service to the Tulsa Area

Retrieved on: 
Thursday, December 8, 2022
Heart, Injury, Urine test strip, Partnership, Paramount, Patient, Degenerative disease, Medical facilities in Tulsa, Electrolyte, CLIA, Caregiver, Holiday, Community Care, Multimedia, COPD, Insurance, Pharmaceutical industry, Medicine, Health insurance, Online shopping

TULSA, Okla. and DENVER, Dec. 8, 2022 /PRNewswire/ --Saint Francis Health System has partnered withDispatchHealth, the nation's first comprehensive in-home medical care provider, to bring a new service to the Tulsa area.

Key Points: 
  • TULSA, Okla. and DENVER, Dec. 8, 2022 /PRNewswire/ --Saint Francis Health System has partnered withDispatchHealth, the nation's first comprehensive in-home medical care provider, to bring a new service to the Tulsa area.
  • DispatchHealth delivers and coordinates high-acuity medical care in the home for a wide range of injuries and illnesses, including viral infections, COPD, gastrointestinal issues, congestive heart failure andmore.
  • Dr. Robertson
    This new in-home care will be available to patients in the Tulsa community beginning Thursday, December 8, 2022.
  • Our partnership with DispatchHealth incorporates all of these pillars in a very accessible and affordable way for our patients."

Urinalysis Market is expected to generate a revenue of USD 3.04 Billion by 2028, Globally, at 7.7% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, November 9, 2022
Diagnosis, Urine test strip, Diabetes, Kidney failure, Color, Viral Research and Diagnostic Laboratories, Pregnancy, CAGR, Market research, Roche Diagnostics, Urinary tract infection, Beckman Coulter, Geography, Clinical urine tests, Time-invariant system, Kidney, USD, Hospital, Urine, Siemens, Mindray, Incidence, Consumables, Product type, Siemens Healthineers, Prevalence, Research, Sysmex Corporation, Institute, Danaher Corporation, Medical device, Medical imaging

JERSEY CITY, N.J., Nov. 9, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Urinalysis Market" By Product Type (Consumables, Instruments), By Test Type (Biochemical Urinalysis, Sediment Urinalysis), By End User (Hospitals and Clinics, Diagnostic Laboratories), By Application (Disease Diagnosis, Pregnancy Tests), and By Geography.

Key Points: 
  • According to an extensive study conducted by Verified Industry Research on the Urinalysis Market, the market size was valued at USD 1.60 Billion in 2020 and is projected to reach USD 3.04 Billion by 2028, growing at a CAGR of 7.7% from 2021 to 2028.
  • Urinalysis is the laboratory process that is used for diagnosis and management of various diseases related to the kidney and urinary tract.
  • During the forecast period, increased testing for urinary tract infections is expected to drive the global market.
  • Verified Market Research has segmented the Global Urinalysis Market On the basis of Product Type, Test Type, End User, Application, and Geography.

Global Urinalysis Market 2022-2026: Growing Adoption of Point-Of-Care Urinalysis Provides Boost to Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Health, Biotechnology, Urine test strip, Prevalence, CAGR, Kidney, Adoption, Cardiac catheterization, Urinary tract infection, Retail

The "Global Urinalysis Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urinalysis Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The urinalysis market is poised to grow by $920.73 mn during 2022-2026, accelerating at a CAGR of 8.04% during the forecast period.
  • The report on the urinalysis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The urinalysis market analysis includes the end-user and product segments and geographic landscape.